GNH USA

Europe — EMA

Imatinib Novumgen

GNH USA supplies Imatinib Novumgen (Imatinib), a tyrosine kinase inhibitor for chronic myeloid leukemia and gastrointestinal stromal tumor.

Imatinib

Request sourcing

1
Pack/s

What is Imatinib?

Imatinib, the active ingredient in Imatinib Novumgen, is a tyrosine kinase inhibitor presented as an oral dosage form for systemic use. It is employed in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, targeting malignant cell proliferation in adult patients.

GNH USA supplies Imatinib Novumgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across markets.

What is Imatinib used for?

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, providing targeted therapy for specific cancers. - Chronic myeloid leukemia (CML): suppresses leukemic cell proliferation and induces remission. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and reduces disease progression. - Dermatofibrosarcoma protuberans (DFSP): promotes tumor regression and improves surgical outcomes. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control in combination regimens. - Other BCR‑ABL positive leukemias: provides therapeutic benefit as part of treatment protocols.

What are the side effects of Imatinib?

Imatinib may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild stomach upset. - Edema: swelling of extremities. - Fatigue: persistent tiredness. - Diarrhea: loose stools. Serious or Rare Side Effects: - Neutropenia: low white blood cell count. - Hepatotoxicity: liver injury. - Cardiac failure: reduced heart function.

What precautions apply to Imatinib?

When prescribing Imatinib, clinicians should observe several safety measures to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes periodically for signs of toxicity. - Evaluate cardiac status: perform ECG or echocardiogram in patients with existing heart disease. - Avoid use in patients with known hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in pregnancy: limited data; weigh potential benefits against risks. - Store at below 25°C: keep in original packaging, protect from moisture and light.

What does Imatinib interact with?

Imatinib interacts with several medicines that can alter its effectiveness or increase toxicity. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib plasma levels, risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce imatinib exposure, risk of treatment failure. - QT‑prolonging agents (e.g., sotalol, quinidine): may exacerbate cardiac rhythm disturbances. Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect, monitor INR. - CYP2C8 substrates (e.g., paclitaxel): possible altered metabolism, adjust dosing if needed. - Antacids containing aluminum or magnesium: may affect absorption, separate administration by at least 2 hours.

Frequently asked questions

What is Imatinib Novumgen used for?+
Imatinib Novumgen is used to treat cancers that are driven by specific tyrosine kinases, most notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It works by targeting the abnormal proteins that promote uncontrolled cell growth in these diseases.
How does Imatinib work?+
Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug halts signaling pathways that lead to malignant cell proliferation, ultimately causing cancer cells to die while sparing most normal cells.
What determines the usual dose of Imatinib Novumgen?+
The dose of Imatinib Novumgen is set by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. No fixed regimen can be stated here; the prescriber tailors the dosage to each individual’s clinical situation.
Is Imatinib safe during pregnancy or breastfeeding?+
Safety data for Imatinib in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be ruled out, the drug is generally avoided unless the therapeutic benefit justifies the potential danger. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.
How do I order Imatinib Novumgen from GNH USA?+
To place an order, submit an enquiry on the Imatinib Novumgen product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.
How does Imatinib compare with the main alternative drug or class?+
Imatinib is the first‑generation BCR‑ABL tyrosine kinase inhibitor and is often compared with second‑generation agents such as dasatinib or nilotinib. While newer TKIs may offer faster molecular responses, Imatinib remains a standard of care because of its well‑characterised safety profile, extensive clinical experience and lower cost in many markets.
What are the recommended storage and handling conditions for Imatinib Novumgen?+
Imatinib Novumgen should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments to maintain its stability.
How is Imatinib Novumgen administered?+
The medication is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber and avoid crushing or chewing the tablet unless directed otherwise.
What are the most serious risks to watch for while taking Imatinib Novumgen?+
The most serious adverse events include severe neutropenia (dangerously low white‑blood‑cell counts), hepatotoxicity (liver injury indicated by elevated enzymes), and cardiac failure, especially in patients with pre‑existing heart disease. Prompt medical attention is required if symptoms such as fever, jaundice, shortness of breath or swelling occur.
Who should not use Imatinib Novumgen?+
Patients with known hypersensitivity to imatinib or any of its excipients should avoid the product. It is also contraindicated in individuals with severe hepatic impairment or uncontrolled cardiac conditions, and should be used with caution in patients with moderate liver disease or a history of cardiac dysfunction.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Imatinib
Route
Oral Use
Manufacturer
Novumgen Limited
Origin
EU

Related products

Imatinib Mesylate 100 mg/1

Imatinib Mesylate 100 mg/1

Imatinib · 100 mg

Imatinib Mesylate
TABLET, FILM COATED
Mylan Pharmaceuticals Inc.
USA
Imatinib Mesylate 400 mg/1

Imatinib Mesylate 400 mg/1

Imatinib · 400 mg

Imatinib Mesylate
TABLET, FILM COATED
Mylan Pharmaceuticals Inc.
USA
Bimatix

Bimatix

Imatinib

Stada Arzneimittel Ag
EU
Bimatix

Bimatix

Imatinib

Stada Arzneimittel Ag
EU